BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

Autor: Timo K van den Berg, Hugo Olsman, Hanke L Matlung, Katka Franke, Imke Lodewijks, Lilian Driessen-Engels, Mary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Ellen Mattaar-Hepp, Marloes E M Stokman, Benny de Wit, Dirk H R F Glaudemans, Daniëlle E J W van Wijk, Lonnie Joosten-Stoffels, Jan Schouten, Paul J Boersema, Monique van der Vleuten, Jorien W H Sanderink, Wendela A Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard J A Rouwendal, Gijs Verheijden, Miranda M C van der Lee, Wim H A Dokter

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)

Background Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. Howev

Externí odkaz: https://doaj.org/article/b070a5b304cf452fb3bfdad0492340e0

Online tests with R/exams: a fundamental tool for STEM (Science, Technology, Engineering and Mathematics) teachers

Autor: Miranda, M. C., Zeileis, A.

Online assessments are an integral part of modern education and their importance has been further amplified during the COVID pandemic. Different phases of the learning and teaching process are often supported by both formative and summative assessmen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2292::3baf3377ca6ed848851007df0fdab404
http://hdl.handle.net/10773/38665

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγon T cells

Autor: Mary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Lilian Driessen-Engels, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Imke Lodewijks, Hugo Olsman, Hanke L Matlung, Katka Franke, Ellen Mattaar-Hepp, Marloes E M Stokman, Benny de Wit, Dirk H R F Glaudemans, Daniëlle E J W van Wijk, Lonnie Joosten-Stoffels, Jan Schouten, Paul J Boersema, Monique van der Vleuten, Jorien W H Sanderink, Wendela A Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard J A Rouwendal, Gijs Verheijden, Miranda M C van der Lee, Wim H A Dokter, Timo K van den Berg

Publikováno v: van Helden, M J, Zwarthoff, S A, Arends, R J, Reinieren-Beeren, I M J, Paradé, M C B C, Driessen-Engels, L, de Laat-Arts, K, Damming, D S, Santegoeds-Lenssen, E W H, van Kuppeveld, D W J, Lodewijks, I, Olsman, H, Matlung, H L, Franke, K, Mattaar-Hepp, E, Stokman, M E M, de Wit, B, Glaudemans, D H R F, van Wijk, D E J W, Joosten-Stoffels, L, Schouten, J, Boersema, P J, van der Vleuten, M, Sanderink, J W H, Kappers, W A, van den Dobbelsteen, D, Timmers, M, Ubink, R, Rouwendal, G J A, Verheijden, G, van der Lee, M M C, Dokter, W H A & van den Berg, T K 2023, ' BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγon T cells ', Journal for Immunotherapy of Cancer, vol. 11, no. 4, jitc-2022-006567 . https://doi.org/10.1136/jitc-2022-006567

BackgroundPreclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. Howeve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f6e6308ed606888d418126a12792c8
https://research.vumc.nl/en/publications/67116c0e-064c-4154-86d3-6797beec296d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.